(10% Negative) IMAGO BIOSCIENCES, INC. (IMGO) Announces Delay in bomedemstat Trials for Total Symptom Score Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment